MS Trust website 23 June 2010 - Source Chicago Breaking Business
Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis.
The first patient - out of 1,500 needed worldwide - was enrolled last month in the US. The drug, daclizumab, is being developed for monthly injection under the patient's skin by North Chicago-based Abbott and Cambridge-based Biogen Idec. Read more here